| pubmed-article:3675606 | pubmed:abstractText | Recent observations indicate that 7 alpha-thiomethylspironolactone is an important circulating metabolite of the mineralocorticoid antagonist spironolactone (SL). Studies were carried out to determine possible sites and pathways of 7 alpha-thiomethyl-SL formation and, in particular, to evaluate SL metabolism by guinea pig hepatic and renal microsomal preparations. In the absence of S-adenosylmethionine (SAM), liver and kidney microsomes rapidly converted SL to 7 alpha-thio-SL as the only metabolite. The rate of 7 alpha-thio-SL production was greater in liver than kidney. In the presence of SAM, 7 alpha-thio-SL was further converted to 7 alpha-thiomethyl-SL by liver and kidney microsomes. The rates of methylation with 7 alpha-thio-SL as substrate were three to four times greater for liver than for kidney, but the Km values were similar (approximately 30 microM) in the two issues. Maximal enzyme activity was obtained with SAM concentrations of 25-200 microM. NADPH had no effect on SL or 7 alpha-thio-SL metabolism by liver or kidney microsomes. To determine if a pathway involving the C-S lyase enzyme might contribute to circulating 7 alpha-thiomethyl-SL levels in vivo, guinea pigs were treated with SL or its dethioacetylated derivative, canrenone, and plasma metabolites were analyzed by HPLC. Both 7 alpha-thiomethyl-SL and canrenone were found to be circulating metabolites in SL-treated animals, but only canrenone was identified in the plasma of canrenone-treated guinea pigs. The results indicate that the liver and kidney are potential sites of 7 alpha-thiomethyl-SL production and that its formation probably does not involve the C-S lyase pathway. | lld:pubmed |
